1
|
Bartlett KE, Hall SR, Rasmussen SA, Crittenden E, Dawson CA, Albulescu LO, Laprade W, Harrison RA, Saviola AJ, Modahl CM, Jenkins TP, Wilkinson MC, Gutiérrez JM, Casewell NR. Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib. Proc Natl Acad Sci U S A 2024; 121:e2315597121. [PMID: 38687786 PMCID: PMC11087757 DOI: 10.1073/pnas.2315597121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Accepted: 02/26/2024] [Indexed: 05/02/2024] Open
Abstract
Snakebite envenoming is a neglected tropical disease that causes substantial mortality and morbidity globally. The venom of African spitting cobras often causes permanent injury via tissue-destructive dermonecrosis at the bite site, which is ineffectively treated by current antivenoms. To address this therapeutic gap, we identified the etiological venom toxins in Naja nigricollis venom responsible for causing local dermonecrosis. While cytotoxic three-finger toxins were primarily responsible for causing spitting cobra cytotoxicity in cultured keratinocytes, their potentiation by phospholipases A2 toxins was essential to cause dermonecrosis in vivo. This evidence of probable toxin synergism suggests that a single toxin-family inhibiting drug could prevent local envenoming. We show that local injection with the repurposed phospholipase A2-inhibiting drug varespladib significantly prevents local tissue damage caused by several spitting cobra venoms in murine models of envenoming. Our findings therefore provide a therapeutic strategy that may effectively prevent life-changing morbidity caused by snakebite in rural Africa.
Collapse
Affiliation(s)
- Keirah E. Bartlett
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Steven R. Hall
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
- Centre for Drugs & Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Sean A. Rasmussen
- Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NSB3H 1V8, Canada
| | - Edouard Crittenden
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Charlotte A. Dawson
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Laura-Oana Albulescu
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
- Centre for Drugs & Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - William Laprade
- Department of Applied Mathematics and Computer Science, Technical University of Denmark, Kongens LyngbyDK-2800, Denmark
| | - Robert A. Harrison
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
- Centre for Drugs & Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Anthony J. Saviola
- Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO80045
| | - Cassandra M. Modahl
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - Timothy P. Jenkins
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens LyngbyDK-2800, Denmark
| | - Mark C. Wilkinson
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| | - José María Gutiérrez
- Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José11501–2060, Costa Rica
| | - Nicholas R. Casewell
- Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
- Centre for Drugs & Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, United Kingdom
| |
Collapse
|
2
|
Rodríguez-Vargas A, Franco-Vásquez AM, Triana-Cerón M, Alam-Rojas SN, Escobar-Wilches DC, Corzo G, Lazcano-Pérez F, Arreguín-Espinosa R, Ruiz-Gómez F. Immunological Cross-Reactivity and Preclinical Assessment of a Colombian Anticoral Antivenom against the Venoms of Three Micrurus Species. Toxins (Basel) 2024; 16:104. [PMID: 38393182 PMCID: PMC10891627 DOI: 10.3390/toxins16020104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 01/27/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024] Open
Abstract
Snakebite accident treatment requires the administration of antivenoms that provide efficacy and effectiveness against several snake venoms of the same genus or family. The low number of immunogenic components in venom mixtures that allow the production of antivenoms consequently gives them partial neutralization and a suboptimal pharmacological response. This study evaluates the immunorecognition and neutralizing efficacy of the polyvalent anticoral antivenom from the Instituto Nacional de Salud (INS) of Colombia against the heterologous endemic venoms of Micrurus medemi, and M. sangilensis, and M. helleri by assessing immunoreactivity through affinity chromatography, ELISA, Western blot, and neutralization capability. Immunorecognition towards the venoms of M. medemi and M. sangilensis showed values of 62% and 68% of the protein composition according to the immunoaffinity matrix, respectively. The analysis by Western blot depicted the highest recognition patterns for M. medemi, followed by M. sangilensis, and finally by M. helleri. These findings suggest that the venom compositions are closely related and exhibit similar recognition by the antivenom. According to enzyme immunoassays, M. helleri requires a higher amount of antivenom to achieve recognition than the others. Besides reinforcing the evaluation of INS antivenom capability, this work recommends the use of M. helleri in the production of Colombian antisera.
Collapse
Affiliation(s)
- Ariadna Rodríguez-Vargas
- Grupo de Investigación en Animales Ponzoñosos y sus Venenos, Instituto Nacional de Salud, Bogotá 111321, Colombia; (M.T.-C.); (S.N.A.-R.); (F.R.-G.)
| | - Adrián Marcelo Franco-Vásquez
- Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Coyoacán, Mexico City 04510, Mexico; (A.M.F.-V.); (F.L.-P.); (R.A.-E.)
| | - Miguel Triana-Cerón
- Grupo de Investigación en Animales Ponzoñosos y sus Venenos, Instituto Nacional de Salud, Bogotá 111321, Colombia; (M.T.-C.); (S.N.A.-R.); (F.R.-G.)
- Bacterial Molecular Genetics Laboratory, Research Department, Universidad El Bosque, Bogotá 110121, Colombia
| | - Shaha Noor Alam-Rojas
- Grupo de Investigación en Animales Ponzoñosos y sus Venenos, Instituto Nacional de Salud, Bogotá 111321, Colombia; (M.T.-C.); (S.N.A.-R.); (F.R.-G.)
| | | | - Gerardo Corzo
- Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico;
| | - Fernando Lazcano-Pérez
- Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Coyoacán, Mexico City 04510, Mexico; (A.M.F.-V.); (F.L.-P.); (R.A.-E.)
| | - Roberto Arreguín-Espinosa
- Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Coyoacán, Mexico City 04510, Mexico; (A.M.F.-V.); (F.L.-P.); (R.A.-E.)
| | - Francisco Ruiz-Gómez
- Grupo de Investigación en Animales Ponzoñosos y sus Venenos, Instituto Nacional de Salud, Bogotá 111321, Colombia; (M.T.-C.); (S.N.A.-R.); (F.R.-G.)
| |
Collapse
|
3
|
Pucca MB, Wen HF, Moura-da-Silva AM, Monteiro WM. Snakebite Clinics and Pathogenesis: From Preclinical to Resource Mapping Studies. Toxins (Basel) 2023; 15:626. [PMID: 37999489 PMCID: PMC10675680 DOI: 10.3390/toxins15110626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 10/22/2023] [Indexed: 11/25/2023] Open
Abstract
Amidst the global healthcare landscape, the menace of snakebite envenoming (SBE) has persisted, silently afflicting millions and annually claiming tens of thousands of lives [...].
Collapse
Affiliation(s)
- Manuela B. Pucca
- Department of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil
| | - Hui F. Wen
- Butantan Institute, São Paulo 05503-900, Brazil; (H.F.W.); (A.M.M.-d.-S.)
| | | | - Wuelton M. Monteiro
- Department of Medicine and Nursing, School of Health Sciences, Dr. Heitor Vieira Dourado Tropical Medicine Foundation, Manaus 69040-000, Brazil
- Department of Teaching and Research, Dr. Heitor Vieira Dourado Tropical Medicine Foundation, Manaus 69040-000, Brazil
| |
Collapse
|
4
|
Corrêa-Netto C, Strauch MA, Monteiro-Machado M, Teixeira-Araújo R, Fonseca JG, Leitão-Araújo M, Machado-Alves ML, Sanz L, Calvete JJ, Melo PA, Zingali RB. Monoclonal-Based Antivenomics Reveals Conserved Neutralizing Epitopes in Type I PLA 2 Molecules from Coral Snakes. Toxins (Basel) 2022; 15:toxins15010015. [PMID: 36668835 PMCID: PMC9863321 DOI: 10.3390/toxins15010015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/18/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022] Open
Abstract
For over a century, polyclonal antibodies have been used to treat snakebite envenoming and are still considered by the WHO as the only scientifically validated treatment for snakebites. Nevertheless, moderate innovations have been introduced to this immunotherapy. New strategies and approaches to understanding how antibodies recognize and neutralize snake toxins represent a challenge for next-generation antivenoms. The neurotoxic activity of Micrurus venom is mainly due to two distinct protein families, three-finger toxins (3FTx) and phospholipases A2 (PLA2). Structural conservation among protein family members may represent an opportunity to generate neutralizing monoclonal antibodies (mAbs) against family-conserved epitopes. In this work, we sought to produce a set of monoclonal antibodies against the most toxic components of M. altirostris venom. To this end, the crude venom was fractionated, and its major toxic proteins were identified and used to generate a panel of five mAbs. The specificity of these mAbs was characterized by ELISA and antivenomics approaches. Two of the generated mAbs recognized PLA2 epitopes. They inhibited PLA2 catalytic activity and showed paraspecific neutralization against the myotoxicity from the lethal effect of Micrurus and Naja venoms' PLA2s. Epitope conservation among venom PLA2 molecules suggests the possibility of generating pan-PLA2 neutralizing antibodies.
Collapse
Affiliation(s)
- Carlos Corrêa-Netto
- Instituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil
- Instituto de Bioquímica Médica Leopoldo de Meis, Instituto Nacional de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
- Correspondence: (C.C.-N.); (R.B.Z.); Tel.: +55-213-938-6782 (R.B.Z.)
| | - Marcelo A. Strauch
- Instituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil
- Programa de Farmacologia e Química Medicinal-UFRJ, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro 21941-902, RJ, Brazil
| | - Marcos Monteiro-Machado
- Programa de Farmacologia e Química Medicinal-UFRJ, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro 21941-902, RJ, Brazil
| | - Ricardo Teixeira-Araújo
- Instituto Vital Brazil, Rio de Janeiro 24230-410, RJ, Brazil
- Instituto de Bioquímica Médica Leopoldo de Meis, Instituto Nacional de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | | | - Moema Leitão-Araújo
- Fundação Zoobotânica do Rio Grande do Sul, Museu de Ciências Naturais, Núcleo Regional de Ofiologia de Porto Alegre, Porto Alegre 90690-000, RS, Brazil
| | - Maria Lúcia Machado-Alves
- Fundação Zoobotânica do Rio Grande do Sul, Museu de Ciências Naturais, Núcleo Regional de Ofiologia de Porto Alegre, Porto Alegre 90690-000, RS, Brazil
| | - Libia Sanz
- Laboratorio de Venómica Estructural y Funcional, Instituto de Biomedicina de Valencia, 46010 Valencia, Spain
| | - Juan J. Calvete
- Laboratorio de Venómica Estructural y Funcional, Instituto de Biomedicina de Valencia, 46010 Valencia, Spain
| | - Paulo A. Melo
- Programa de Farmacologia e Química Medicinal-UFRJ, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro 21941-902, RJ, Brazil
| | - Russolina Benedeta Zingali
- Instituto de Bioquímica Médica Leopoldo de Meis, Instituto Nacional de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
- Correspondence: (C.C.-N.); (R.B.Z.); Tel.: +55-213-938-6782 (R.B.Z.)
| |
Collapse
|